[Cost-benefit aspects of taxane therapy].
Dietrich
Eva Susanne
ES
Leiterin Abteilung Arzneimittel, Kassenärztliche Bundesvereinigung, Berlin. edietrich@kbv.de
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D000077143:Docetaxel; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000523:psychology; D011788:Quality of Life; D043823:Taxoids / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel